Trevena Starts Heart Failure Drug Study

Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, announced the initiation of a Phase IIa clinical trial with its lead program TRV120027.

Trevena has started a Phase IIa clinical trial to evaluate TRV120027 as a treatment for acute heart failure. The goal of the study is to demonstrate that TRV120027 rapidly and predictably improves hemodynamics while improving cardiac output and protecting renal function.

The randomised, placebo-controlled, double-blind, dose-ranging trial will evaluate the haemodynamic effects of TRV120027 in patients with stable heart failure. The study is expected to enrol approximately 32 patients.

The primary endpoints of the study are evaluation of the safety and tolerability of TRV120027 and the measurement of its effects on pulmonary capillary wedge pressure.